Pharmaceutical

J&J seeks EU approval for new Darzalex multiple myeloma indication

J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.

Mar 7, 2024 - 18:00
J&J seeks EU approval for new Darzalex multiple myeloma indication
J&J submitted a new application to the EMA for the approval of its Darzalex combination therapy for multiple myeloma.
Read the original article

Tags:

Previous Article

Alumis secures $259m to develop therapies for immune dysfunction

Next Article

Avacta Group files patent for extended circulating serum half-life therapeutic c...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA’s Woodcock reflects on more than 30 years at agency — and hints at what’s next

STAT+: FDA’s Woodcock reflects on more than 30 years at...

Jan 30, 2024

STAT+: New research may give geneticists a long-sought tool: a targeted protein delivery device

STAT+: New research may give geneticists a long-sought ...

Mar 30, 2023

STAT+: With momentum on Alzheimer’s therapies, Europe sees delivery challenges ahead, too

STAT+: With momentum on Alzheimer’s therapies, Europe s...

Jul 14, 2023